MGMT and neoplasm: Thus, the presence or absence of MGMT is considered a prognostic factor for GBM patients, as tumor cells with epigenetic silencing of the Mgmt promoter (i.e., MGMT-methylated) are more susceptible to DNA damage than those that express Mgmt (i.e., MGMT-unmethylated) [8–10].